분화갑상선암과 방사성요오드: 과거, 현재 그리고 미래

키워드

참고문헌 (39)

1. Fahey FH, "Saul Hertz, MD, and the birth of radionuclide therapy", EJNMMI Phys, 4(1), pp.15~ (2017)
2. Hertz S, "Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism", J Am Med Assoc, 131, pp.81~86 (1946)
3. Chapman EM, "The treatment of hyperthyroidism with radioactive iodine", J Am Med Assoc, 131, pp.86~91 (1946)
4. Seidlin SM, "Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid", CA Cancer J Clin, 40(5), pp.299~317 (1990)
5. Dai G, "Cloning and characterization of the thyroid iodide transporter", Nature, 379(6564), pp.458~460 (1996)
6. Smanik PA, "Cloning of the human sodium lodide symporter", Biochem Biophys Res Commun, 226(2), pp.339~345 (1996)
7. Reynolds JC, "The changing role of radioiodine in the management of differentiated thyroid cancer", Semin Nucl Med, 27(2), pp.152~164 (1997)
8. Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97(5), pp.418~428 (1994)
9. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
10. Sawka AM, "An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer", Endocrinol Metab Clin North Am, 37(2), pp.457~480 (2008)
11. Sacks W, "The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008", Thyroid, 20(11), pp.1235~1245 (2010)
12. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
13. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
14. Ahn HS, "Korea's thyroid-cancer "epidemic"--screening and overdiagnosis", N Engl J Med, 371(19), pp.1765~1767 (2014)
15. Haugen BR, "American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
16. Haugen BR, "American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed?", Cancer, 123(3), pp.372~381 (2017)
17. Haugen BR, "American Thyroid Association guidelines on the management of thyroid nodules and differentiated thyroid cancer task force review and recommendation on the proposed renaming of encapsulated follicular variant papillary thyroid carcinoma without invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features", Thyroid, 27(4), pp.481~483 (2017)
18. Jeong SY, "Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms", Thyroid, 23(5), pp.609~616 (2013)
19. Yu CY, "A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer", Thyroid (2018)
20. Zhang Y, "Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis", Nucl Med Commun, 37(2), pp.110~115 (2016)
21. Molenaar RJ, "Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer", J Clin Oncol, 36(18), pp.1831~1839 (2018)
22. Verburg FA, "I-131 as adjuvant treatment for differentiated thyroid carcinoma may cause an increase in the incidence of secondary haematological malignancies: an "inconvenient" truth?", Eur J Nucl Med Mol Imaging, 45(13), pp.2247~2249 (2018)
23. Frangos S, "Acknowledging gray areas: 2015 vs. 2009American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients", Eur J Nucl Med Mol Imaging, 44(2), pp.185~189 (2017)
24. Verburg FA, "Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer", Eur J Nucl Med Mol Imaging, 43(6), pp.1001~1005 (2016)
25. 이가희, "2016년 대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안", International Journal of Thyroidology, 9(2), pp.59~126 (2016), 대한갑상선학회
26. 이가희, "The Revised 2016 Korean Thyroid Association Guidelines for Thyroid Nodules and Cancers: Differences from the 2015 American Thyroid Association Guidelines", Endocrinology and Metabolism, 31(3), pp.373~378 (2016), 대한내분비학회
27. Kiyota N, "Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial", Thyroid, 27(9), pp.1135~1141 (2017)
28. Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
29. Van Nostrand D, "Selected controversies of radioiodine imaging and therapy in differentiated thyroid cancer", Endocrinol Metab Clin North Am, 46(3), pp.783~793 (2017)
30. Freudenberg LS, "Clinical applications of I-124-PET", CT in patients with differentiated thyroid cancer, 2011, pp.38(Suppl 1), S48~S56
31. Ho AL, "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer", N Engl J Med, 368(7), pp.623~632 (2013)
32. Dunn LA, "Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers", J Clin Endocrinol Metab, 104(5), pp.1417~1428 (2019)
33. Tuttle RM, "Controversies, consensus, and collaboration in the use of I-131 therapy in differentiated thyroid cancer: a joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association", Thyroid, pp.461~470 (2019)
34. Mauri G, "Laser and radiofrequency ablations for benign and malignant thyroid tumors", Int J Hyperthermia, 36(2), pp.13~20 (2019)
35. Kornas RC, "A peculiar case of the abscopal effect: radioactive iodine therapy incidentally palliating marginal zone lymphoma", Case Rep Oncol Med, 2015, pp.281729~ (2015)
36. Luster M, "European perspective on 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:Proceedings of an Interactive International Symposium", Thyroid, 29(1), pp.7~26 (2019)
37. Ruel E, "Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer", J Clin Endocrinol Metab, 100(4), pp.1529~1536 (2015)
38. Schlumberger M, "Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial", Lancet Diabetes Endocrinol, 6(8), pp.618~626 (2018)
39. Dehbi HM, "Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial", Lancet Diabetes Endocrinol, 7(1), pp.44~51 (2019)

관련 논문AI추천